Understanding treatments and outcomes in patients with primary cutaneous lymphoma
Treatments and Outcomes in Patients With Primary Cutaneous Lymphoma: a Nationwide Multi-center Prospective Study in China
This study is trying to find out how well different treatments work for people with primary cutaneous lymphoma in China to help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 5 sites (Beijing, Beijing Municipality and 4 other locations) |
| Trial ID | NCT05518851 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the diagnosis and treatment of primary cutaneous lymphoma (PCL) in China by establishing a standardized center for PCL. It will systematically assess the current treatment status and outcomes of patients diagnosed with PCL, which includes various types of cutaneous T-cell and B-cell lymphomas. The study will gather data from multiple medical centers to evaluate the efficacy and safety of different treatment methods, addressing the limited data available for Chinese patients with PCL.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed pathological diagnosis of primary cutaneous lymphoma from participating medical centers.
Not a fit: Patients who are unable to provide informed consent or cannot complete the required questionnaires may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies and improve patient outcomes for those with primary cutaneous lymphoma.
How similar studies have performed: While there have been studies on primary cutaneous lymphoma, this nationwide multi-center approach focusing on Chinese patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients from the participatin medical centers that has passed the data review of the National Clinical Center for Skin and Immune Diseases. * Patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy. Exclusion Criteria: * Patients who fail to provide informed consent form. * Patients who cannot complete the questionnaire independently or under the guidance of investigators.
Where this trial is running
Beijing, Beijing Municipality and 4 other locations
- Peking University Third Hospital — Beijing, Beijing Municipality, China (Recruiting)
- SUN YAI-SEN Memorial Hospital, SUN YAI-SEN University — Guandong, Guangdong, China (Recruiting)
- Hospital for Skin Disease, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College — Nanjing, Jiangsu, China (Recruiting)
- Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)
- Peking University First Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Yang Wang, MD — Peking University First Hospital
- Study coordinator: Yang Wang, MD
- Email: yangwang_dr@bjmu.edu.cn
- Phone: (86)-10-83572350
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.